Research programme: antisense drug therapies - Isis/Eli Lilly

Drug Profile

Research programme: antisense drug therapies - Isis/Eli Lilly

Latest Information Update: 29 Mar 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Eli Lilly
  • Class Antisense oligonucleotides
  • Mechanism of Action Apoptosis stimulants; RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 29 Mar 2012 No development reported - Preclinical for Cancer in USA (Parenteral)
  • 14 Apr 2009 Preclinical development is ongoing
  • 20 Sep 2004 Isis Pharmaceuticals has licensed LY 2275796 to Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top